A combination of cisplatin, methotrexate, bleomycin, and vincristine (CABO) was assessed in advanced epidermoid head and neck cancer. Among 72 patients with recurrent or metastatic disease and measurable lesions, there were 9 complete and 27 partial responses for an overall response rate of 50%. The
Phase II study with IL-2 combined with vincristine, bleomycin, and methotrexate (VBM) in recurrent head and neck carcinomas
✍ Scribed by G. Gambaro; P. Bagnasacco; A. Ballarè; L. Turri; A. Prino; G. Oro; M. Krengli
- Book ID
- 117667640
- Publisher
- Elsevier Science
- Year
- 1999
- Tongue
- English
- Weight
- 142 KB
- Volume
- 35
- Category
- Article
- ISSN
- 0959-8049
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## For the EORTC Head and Neck Cooperative Group A total of 185 eligible patients with advanced inoperable squamous cell carcinoma of the head and neck were randomized into two groups; the cisplatin, methotrexate, bleomycin, and vincristine (CABO) group received cisplatin (50 mg/m2; day 4), methot
Thirty patients with recurrent and/or metastatic head and neck cancer were treated with sequentially administered methotrexate (MTX) and piritrexim (PTX). The treatment schedule consisted of intravenous (IV) MTX (50 mg/m') administered on day 1 and oral PTX (75 mg/mz) administered twice daily on day
Carboplatin is a platinum analogue with activity reported in head and neck cancer. We conducted a phase II trial with 14 patients who had recurrent head and neck cancer. They were treated with carboplatin 300 mg/m2 intravenously (I.V.) and bleomycin 30 units I.V. every 4 weeks. No responses were obs